Oxford, UK – 16 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene and cell therapy company, was informed that on 13 March 2015 one of its Directors acquired ordinary shares of 1p each (“Ordinary Shares”) as follows:
Director / PDMR Paul Blake
Title
Chief Development Officer
Price per share (p) 10.25p
Number of Ordinary Shares acquired on
25 November 2014 97,560
Interest after purchase
Number of Ordinary Shares 2,624,559
% of total
issued share capital
0.10%
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Media Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 7309 5700
Notes for editors
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company’s industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Help employers find you! Check out all the jobs and post your resume.
